Navigation Links
General Notes on Primer Design in PCR*

t can promote non-specific annealing. Poly A and Poly T stretches are also to be avoided as these will breath and open up stretches of the primer-template complex. This can lower the efficiency of amplification. Polypyrimidine (T, C) and polypurine (A, G) stretches should also be avoided. Ideally the primer will have a near random mix of nucleotides, a 50% GC content and be ~20 bases long. This will put the Tm in the range of 56C 62C(1).

3-end Sequence

It is well established that the 3' terminal position in PCR primers is essential for the control of mis-priming(5). We have already explored the problem of primer homologies occurring at these regions. Another variable to look at is the inclusion of a G or C residue at the 3' end of primers. This GC Clamp helps to ensure correct binding at the 3' end due to the stronger hydrogen bonding of G/C residues. It also helps to improve the efficiency of the reaction by minimizing any breathing that might occur.

Conclusion

It is essential that care is taken in the design of primers for PCR. Several parameters including the length of the primer, %GC content and the 3' sequence need to be optimized for successful PCR. Certain of these parameters can be easily manually optimized while others are best done with commercial computer programs. In any event, careful observance of the general rules of primer design will help ensure successful experiments.

References
  1. Dieffenbach, C.W., Lowe, T.M.J., Dveksler, G.S., General Concepts for PCR Primer Design, in PCR Primer, A Labo
    '"/>


Source:


Page: All 1 2 3 4 5 6

Related biology technology :

1. General Considerations for Successful Transfection Experiments
2. Real-Time PCR: General Considerations, Rev A
3. Eppendorf Electroporation Application Notes Your participation is highly welcome !!!
4. Eppendorf Electroporation Application Notes Your participation is highly welcome !!!
5. Control RT-PCR Primers for Human Gene Transcripts with Varying Abundance
6. RT-PCR Primer Sets for Human and Mouse Mismatch Repair Genes
7. Gene-Specific Primers for NMDA Receptor Subunits
8. RT-PCR Primers for the Study of Apoptosis
9. New PCR Primers for Human Diseases
10. Amplification of Epstein-Barr Virus Exon C with Difficult Primers Using Eppendorf Mastercycler gradient
11. Human t-PA Control Primer Set
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: General Notes Primer Design PCR

(Date:7/30/2015)... According to a new market ... PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), ... by End Users - Global Forecast to 2020", published ... USD 2,107.99 million by 2020 from USD 1,034.93 million ... Browse more than 75 ...
(Date:7/30/2015)... 30, 2015 Ascendis Pharma A/S (Nasdaq: ... its innovative TransCon technology to address significant unmet ... a six-month Phase 2 study to evaluate the ... in 53 treatment-naïve, pre-pubertal children with growth hormone ... pleased with the top-line results from our Phase ...
(Date:7/29/2015)... , July 30, 2015 ... results for the second quarter of 2015. CEO ... results and its performance in different businesses. ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Topics covered ... results - Performance drivers ...
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... the Company,s Chief Financial Officer has resigned.  The Company ... Financial Officer who retired in December 2014, as full ... a permanent successor.     Andy Ashworth ... and ensure a smooth transition.  Andy was the Company,s ...
Breaking Biology Technology:Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3
... Physicists at the University of California, Berkeley, have built the ... the diameter of a human hair that requires only a ... , The scientists successfully received their first FM broadcast last ... Boys, "Good Vibrations" transmitted from across the room. In homage ...
... 31 /PRNewswire-FirstCall/ - Dragon Pharmaceutical Inc.,(TSX: DDD; ... its biotech method,for 7ACA production has been ... believes this achievement validates the Company,s research,and ... This,technology would bring immediate benefits to production ...
... CRANBURY, N.J., Oct. 31 Amicus Therapeutics,(Nasdaq: ... small molecule,orally-active pharmacological chaperones for the treatment ... for the third quarter of 2007.,On a ... Generally Accepted,Accounting Principles (GAAP), Amicus announced a ...
Cached Biology Technology:World's smallest radio uses single nanotube to pick up good vibrations 2World's smallest radio uses single nanotube to pick up good vibrations 3World's smallest radio uses single nanotube to pick up good vibrations 4Dragon Announces R&D Achievement in Biotech Manufacturing Process 2Dragon Announces R&D Achievement in Biotech Manufacturing Process 3Amicus Therapeutics Announces Third Quarter 2007 Financial Results 2Amicus Therapeutics Announces Third Quarter 2007 Financial Results 3Amicus Therapeutics Announces Third Quarter 2007 Financial Results 4Amicus Therapeutics Announces Third Quarter 2007 Financial Results 5Amicus Therapeutics Announces Third Quarter 2007 Financial Results 6Amicus Therapeutics Announces Third Quarter 2007 Financial Results 7Amicus Therapeutics Announces Third Quarter 2007 Financial Results 8
(Date:7/21/2015)... , July 21, 2015 Today, ZTE ... Already received as well as expected revenues in 2015 that relate ... FPC,s communicated revenue guidance of approximately 2,200 MSEK for 2015. ... is a leading smartphone manufacturer in China ... FPC1 02 5 for Axon , ...
(Date:7/13/2015)... 13, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, ... 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION METHOD AND ... and secure method to make payments.  With this ... introduced with its groundbreaking voice-direct payment patent application, ...
(Date:7/8/2015)... , July 8, 2015 Summary Pancreatic ... the fourth most fatal, with a mortality rate of ... prognosis of pancreatic cancer patients has highlighted a significant ... is not being met by the current market. ... of products with varying molecule types and mechanisms of ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
... the University of Leeds, UK, the Charit University Medical ... Medicine (MDC) in Berlin, Germany, have discovered a new ... identified how ,junk, DNA promotes the growth of cancer ... (University of Leeds) and Dr Stephan Mathas (Charit, MDC) ...
... estimated that nearly 1.5 million Americans have been diagnosed with ... are believed to have some form of autism, according to ... and Prevention (CDC). Find out what new research and treatment ... ASD seen over the past few decades at a panel ...
... Heart and liver transplant recipients are at particularly ... donated organ, researchers report at the 2nd European Lung ... such cancers in these patients to maximize the chance ... for decades that the immunosuppressive drugs given to transplant ...
Cached Biology News:'Junk DNA' drives cancer growth 2Expert panel to discuss autism spectrum disorders 2Lung cancer risk particularly high for heart and liver transplant recipients 2
... PHD2000 syringe pump series combines Harvard Apparatuss best ... and a wide range of configuration options. A ... dimensions of syringes from all the major manufacturers. ... all the pertinent information from across the lab. ...
Mouse monoclonal antibody to RAD51L3 - RAD51-like 3 (S. cerevisiae)...
... you to store and manage very large ... secure central relational database. Storing and managing ... resource for clone tracking and enables you ... analysis. LabShare software integrates seamlessly with Invitrogen's ...
... A and Protein G bind specifically to ... A and Protein G conjugates are commonly ... (antibodies) and immunoglobulin subtypes from serum, hybridoma ... biological fluids. These reagents are also commonly ...
Biology Products: